nurandociguat (BAY 3283142) / Bayer - LARVOL DELTA

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=75 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

NO- and Heme-Independent sGC Activators, Runcaciguat and Nurandociguat, as New Treatment Options for CKD: From Bench to Bedside (KIDNEY WEEK 2025) - P2 | "Conclusion These non-clinical and first clinical data strongly suggest that sGC activators could become an effective treatment option for CKD patients which can significantly reduce the residual risk of patients on top of optimized current therapies. Currently, nurandociguat is investigated clinically a phase 2 program in CKD patients (NCT06522997)."

Chronic Kidney Disease • Diabetic Nephropathy • Nephrology • Renal Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2025 ➔ Nov 2025 | Trial primary completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Hepatology • Nephrology • Renal Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Bayer | Trial completion date: Jun 2026 ➔ Mar 2026 | Trial primary completion date: May 2026 ➔ Feb 2026

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2026 ➔ Jun 2026

Enrollment open • Trial completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Chronic Kidney Disease • Diabetic Retinopathy • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease • Retinal Disorders

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Not yet recruiting | Sponsor: Bayer

New P2 trial • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Hepatology • Nephrology • Renal Disease

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Cardiovascular • Chronic Kidney Disease • Diabetic Retinopathy • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease • Retinal Disorders

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Hepatology • Nephrology • Renal Disease

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Recruiting ➔ Completed | N=36 ➔ 24

Enrollment change • Trial completion • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Bayer | Trial primary completion date: Jun 2023 ➔ Mar 2023

Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Nephrology • Renal Disease

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Nephrology • Renal Disease

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Bayer | Trial completion date: Sep 2023 ➔ May 2023

Trial completion date • Chronic Kidney Disease • Nephrology • Renal Disease